“ABS has an impressive infrastructure and technological capabilities for generation of quality antibodies. BERG in actively using ABS generated antibodies in various programs focused on drug and biomarker discovery, target validation and drug development program and look forward to continued engagement with ABS to support our initiatives.”

Rangaprasad Sarangarajan, SVP & Chief Scientific Officer